Combination of Lanosterol and Nilvadipine Nanosuspensions Rescues Lens Opacification in Selenite-Induced Cataractic Rats.
cataract
lanosterol
nanosuspensions
nilvadipine
selenite-induced cataractic rat
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
21 Jul 2022
21 Jul 2022
Historique:
received:
14
06
2022
revised:
20
07
2022
accepted:
20
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
It has recently been reported that lanosterol (LAN) plays a preventive role against lens opacification through the reversal of crystalline aggregation. However, the effect of LAN is not sufficient to restore lens transparency. In this study, we designed ophthalmic nanosuspensions (LAN-ONSs and NIL-ONSs) based on LAN and nilvadipine (NIL), which can counteract cataract-related factors (e.g., enhanced Ca
Identifiants
pubmed: 35890415
pii: pharmaceutics14071520
doi: 10.3390/pharmaceutics14071520
pmc: PMC9318002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 21K06656
Références
Biol Pharm Bull. 2008 Nov;31(11):1990-5
pubmed: 18981561
MAbs. 2019 May/Jun;11(4):709-724
pubmed: 30939981
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4639-43
pubmed: 14578379
Nature. 2015 Jul 30;523(7562):607-11
pubmed: 26200341
J Oleo Sci. 2015;64(7):743-50
pubmed: 26136174
Int J Mol Sci. 2020 Feb 05;21(3):
pubmed: 32033321
Int J Pharm. 2009 Jan 5;365(1-2):143-9
pubmed: 18773948
Philos Trans R Soc Lond B Biol Sci. 2011 Apr 27;366(1568):1278-92
pubmed: 21402586
Invest Ophthalmol Vis Sci. 1987 Oct;28(10):1702-6
pubmed: 2820891
Toxicol Appl Pharmacol. 1984 Jun 15;74(1):109-15
pubmed: 6729815
Experientia. 1978 Feb 15;34(2):222-3
pubmed: 624358
J Control Release. 2009 Aug 4;137(3):217-23
pubmed: 19393270
Pharmaceutics. 2020 Jul 04;12(7):
pubmed: 32635523
Bull World Health Organ. 2001;79(3):249-56
pubmed: 11285671
Biol Pharm Bull. 2014;37(2):306-10
pubmed: 24492726
Int Ophthalmol. 2008 Aug;28(4):247-60
pubmed: 17712529
J Vis Exp. 2018 Jul 29;(137):
pubmed: 30102270
Pharmaceutics. 2021 Nov 25;13(12):
pubmed: 34959281
Invest Ophthalmol Vis Sci. 2007 Jan;48(1):88-95
pubmed: 17197521
Mol Vis. 1997 Jul 23;3:8
pubmed: 9238097
Invest Ophthalmol Vis Sci. 2000 May;41(6):1460-6
pubmed: 10798663
Animal Model Exp Med. 2018 Jul 28;1(2):100-108
pubmed: 30891554
Toxicology. 2008 May 21;247(2-3):139-44
pubmed: 18403084
Exp Eye Res. 1981 Nov;33(5):505-14
pubmed: 7318950
Curr Eye Res. 1987 Feb;6(2):289-300
pubmed: 3032516
J Control Release. 2010 Aug 3;145(3):297-305
pubmed: 20420865
Toxicology. 2014 May 7;319:53-62
pubmed: 24598350
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2255-61
pubmed: 10892870
FEBS Lett. 1993 Jun 21;324(3):265-70
pubmed: 8405363
Macromol Biosci. 2015 Dec;15(12):1663-72
pubmed: 26271011
Science. 2015 Nov 6;350(6261):674-7
pubmed: 26542570
Trends Mol Med. 2012 May;18(5):273-82
pubmed: 22520268
Lancet. 2017 Aug 5;390(10094):600-612
pubmed: 28242111
Invest Ophthalmol Vis Sci. 1990 Nov;31(11):2405-11
pubmed: 2173688
Eur J Pharm Biopharm. 2011 Sep;79(1):119-25
pubmed: 21303692
Mini Rev Med Chem. 2015;16(3):241-57
pubmed: 26586128